Please note that the date you requested in the address for this web page is not an actual date upon which a change occurred to this item of legislation. You are being shown the legislation from , which is the first date before then upon which a change was made.
5. Unless paragraphs 6 to 10 apply, the fee payable under regulation 37(3) in connection with the holding of a marketing authorisation relating to a medicinal product of a kind described in column 1 of the following table is the applicable fee specified in the corresponding entry in column 2 of that table.
| Column 1 Type of Medicinal Product | Column 2 Fee payable | |||
|---|---|---|---|---|
| 1. New Active Substance | £24,821 | |||
| 2. Parallel Import | £323 | |||
| 3. Others | ||||
| (a) | Any product (not being a derivative of a new active substance) in respect of which a marketing authorisation has been granted in consequence of a complex application submitted on or after 1st April 1989 | £10,221 | ||
| (b) | Prescription Only Medicine | |||
| (i) | Standard Fee | £2,556 | ||
| (ii) | Reduced Rate Fee | £1,275 | ||
| (iii) | Lower Fee | £323 | ||
| (c) | Pharmacy | £323 | ||
| (d) | General Sale List | £323 | ||
| (e) | Herbal remedy | £80 | ||
| (f) | Traditional herbal registrations | £80 | ||
| (g) | National homoeopathic product | £80 | ||
| (h) | Homoeopathic or anthroposophic product which is the subject of a licence of right | £80 | ||
6. In the case of an article or substance to which Part 2 of the Act applies by virtue of the Medicines (Surgical Materials) Order 1971 M1, the fee payable under regulation 37(3) in connection with the holding of a marketing authorisation or licence is £323.
Marginal Citations
M1S.I. 1971/1267: Part 2 of the Act is applied by article 3 of the Order which has been amended by S.I. 1994/3119, 2004/1031 and 2006/2407. Provisions of Part 2 of the Act that were repealed under Schedule 35 (repeals and revocations) to the Human Medicines Regulations 2012 are applied to the extent provided for under paragraph 1 of Schedule 32 (transitional provisions and savings) to those Regulations.
7. Unless paragraph 8 applies, where a marketing authorisation is held in respect of a derivative of a new active substance, the fee payable under regulation 37(3) is—
(a)£10,221 where the medicinal product to which the authorisation relates has a different route of administration from that of the new active substance; or
(b)£6,899 in any other case.
8.—(1) The fee specified in—
(a)paragraph 5 for a new active substance; and
(b)in paragraph 7 for a derivative of a new active substance,
is only payable for the five relevant fee periods following that in which the marketing authorisation is granted.
(2) The fee payable in accordance with entry 3(a) of the table set out in paragraph 5 is only payable for the three relevant fee periods following the year beginning 1st April during which the marketing authorisation is granted.
(3) Where a marketing authorisation is surrendered and at the same time another marketing authorisation held by the authorisation holder is varied so as to include in that other authorisation the provisions of the first authorisation, the fee payable—
(a)for the five relevant fee periods following the fee period during which the marketing authorisation is granted is the fee specified at entry 1 of the table set out in paragraph 5, where the first authorisation relates to a new active substance;
(b)in all other cases, for each fee period mentioned in sub-paragraph (2), is the fee specified at entry 3(a) of that table.
(4) In respect of fee periods following those referred to in sub-paragraphs (1) to (3) of this paragraph, the periodic fees are the appropriate fees for the kind of medicinal product in question specified in entries 3(b), (c) or (d) of the table set out in paragraph 5.
(5) In connection with the holding of a marketing authorisation in respect of a limited use drug or a derivative of a limited use drug—
(a)where the total value of the product sold or supplied exceeds £200,000, until the expiry of the five relevant fee periods following the fee period during which the marketing authorisation was granted, the periodic fee payable is the fee that would be payable if the drug were, respectively, a new active substance or a derivative of a new active substance;
(b)where the total value of the product sold or supplied does not exceed £200,000 or where a periodic fee has been payable in respect of the limited use drug or derivative of a limited use drug for five relevant fee periods following the fee period during which the marketing authorisation was granted, the periodic fee payable is the fee payable in respect of a prescription only medicine in accordance with entry 3(b)(i) of the table set out in paragraph 5.
9. Where a marketing authorisation relates to any two or more medicinal products of a kind described in entries 3(b), (c) or (d) of column 1 of the table in paragraph 5, the fee payable under regulation 37(3) shall be the lower of the fee specified as corresponding to those entries in column 2 of that table.
10. Where a reduced rate fee or a lower fee may be payable in respect of any relevant fee period and an authorisation holder does not submit information about the total value of the product sold or supplied in relation to the relevant calendar year to the satisfaction of the licensing authority, the periodic fee payable shall, where applicable, be the standard fee for each description of medicinal product in respect of which a marketing authorisation is held by the authorisation holder.
11.—(1) Unless sub-paragraph (3) applies, the fee payable under regulation 37(3) in connection with the holding of a manufacturer's licence is £493.
(2) The fee payable under regulation 37(3) in connection with the holding of a manufacturing authorisation is £493.
(3) The fee payable under regulation 37(3) in connection with the holding of a manufacturer's licence which relates to the import of special medicinal products from a third country is the fee payable in accordance with sub-paragraph (1) and an additional amount calculated in accordance with paragraph 15.
12.—(1) Subject to sub-paragraph (2) and to paragraphs 13 and 16, the fee payable under regulation 37(3) in connection with the holding of a wholesale dealer's licence is £303.
(2) The fee payable under regulation 37(3) is £181 where the wholesale dealer's licence—
(a)relates to anything done in a registered pharmacy by or under the supervision of a pharmacist and amounts to wholesale dealing, where such dealing constitutes no more than 15% of the total value of the sale of authorised medicinal products carried on at that pharmacy;
(b)does not relate to anything done in a registered pharmacy, where the total value of the sale by way of wholesale dealing in authorised medicinal products does not exceed £35,000; or
(c)relates to general sale list medicines only.
(3) For the purposes of sub-paragraph (2), the total value shall be calculated in accordance with Part 2 of this Schedule and the references to “marketing authorisation” and “authorisation holder” in Part 2 shall be interpreted as if they were references to “wholesale dealer's licence” and “licence holder”, respectively.
13. Where in respect of any relevant fee period, the holder of a wholesale dealer's licence does not submit evidence of turnover in relation to the relevant fee period to the satisfaction of the licensing authority, the periodic fee payable shall be the fee prescribed in paragraph 12(1).
14. The fee payable under regulation 37(3) in connection with the holding of a wholesale dealer's licence which relates to special medicinal products imported from another EEA member State is the fee payable in accordance with paragraphs 12 and 13 and an additional amount calculated in accordance with paragraph 15.
15.—(1) The additional amount referred to in paragraph 11(3) and 14 in relation to any fee period shall be the fee specified in the entry in column 2 of the following table corresponding to the estimated number of special import notices for that fee period specified in column 1.
| Column 1 Number of special import notices | Column 2 Additional amount |
|---|---|
| 1 to 20 | £130 |
| 21 to 100 | £519 |
| 101 to 1,000 | £2,077 |
| 1,001 to 5,000 | £10,383 |
| 5,001 to 20,000 | £25,957 |
| 20,001 to 50,000 | £51,914 |
| 50,001 to 100,000 | £103,828 |
| 100,001 or more | £155,742 |
(2) For the purposes of this paragraph, the estimated number of special import notices for any fee period shall be the number notified in writing to the licence holder by the licensing authority before the start of that fee period as the number of such notices which the authority estimate will be given by the holder during the fee period.
16. The fee payable under regulation 37(3) in connection with the holding of a traditional herbal registration is £80.